How To Use HCPCS Code C9480

HCPCS code C9480 describes an injection of trabectedin, with a dosage of 0.1 mg. This code is used to identify the administration of this specific medication in a medical setting. Trabectedin is a chemotherapy drug that is used to treat certain types of cancer, including soft tissue sarcoma. It works by interfering with the growth and spread of cancer cells in the body.

1. What is HCPCS C9480?

HCPCS code C9480 is a specific code that is used to identify the injection of trabectedin, with a dosage of 0.1 mg. It is important for medical coders to use this code accurately to ensure proper billing and reimbursement for the administration of this medication.

2. Official Description

The official description of HCPCS code C9480 is “Injection, trabectedin, 0.1 mg”. The short description for this code is “Parenteral supp not othrws c”. This description accurately represents the specific medication and dosage that is being administered.

3. Procedure

1. Prepare the medication: The healthcare provider will prepare the trabectedin medication according to the manufacturer’s instructions.
2. Verify patient information: The provider will verify the patient’s identity and ensure that the correct medication and dosage are being administered.
3. Administer the injection: The provider will administer the trabectedin injection to the patient. This may be done through a vein (intravenous) or into a muscle (intramuscular), depending on the specific instructions for the medication.
4. Monitor the patient: After the injection, the provider will closely monitor the patient for any adverse reactions or side effects.

4. When to use HCPCS code C9480

HCPCS code C9480 should be used when the healthcare provider administers an injection of trabectedin with a dosage of 0.1 mg. It is important to ensure that the medication and dosage match the description provided in the code. This code should only be used for the specific medication and dosage mentioned and should not be used for any other medications or dosages.

5. Billing Guidelines and Documentation Requirements

When billing for the administration of trabectedin using HCPCS code C9480, healthcare providers should ensure that the following documentation is included:

• Documentation of the patient’s medical condition and the need for the medication
• Date and time of the administration
• Dosage of trabectedin administered
• Route of administration (intravenous or intramuscular)
• Any additional services or supplies provided during the administration

6. Historical Information and Code Maintenance

HCPCS code C9480 was added to the Healthcare Common Procedure Coding System on January 01, 1985. It has an effective date of January 01, 1996. This code was terminated on December 31, 2016. The termination of this code means that it is no longer valid for use in medical coding and billing.

7. Medicare and Insurance Coverage

HCPCS code C9480 may have specific coverage instructions that apply, as indicated by the coverage code D. It is important for healthcare providers to review the specific coverage guidelines for this code to ensure proper reimbursement. The pricing indicator code for this code is 57, which indicates that it is priced by other carriers. The multiple pricing indicator code is A, which means that it is not applicable as HCPCS priced under one methodology.

8. Examples

Here are five examples of when HCPCS code C9480 should be billed:

1. A patient with soft tissue sarcoma receives an intravenous injection of trabectedin with a dosage of 0.1 mg.
2. A healthcare provider administers an intramuscular injection of trabectedin with a dosage of 0.1 mg to a patient with a specific type of cancer.
3. A patient undergoes a chemotherapy session and receives an intravenous injection of trabectedin as part of their treatment plan.
4. A healthcare provider administers an intramuscular injection of trabectedin to a patient during a surgical procedure.
5. A patient with advanced cancer receives an intravenous injection of trabectedin with a dosage of 0.1 mg as part of their palliative care.